Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial. Issue 11 (8th September 2014)

• Record Type: Journal Article
• Authors: Omata, Masao; Nishiguchi, Shuhei; Ueno, Yoshiyuki; Mochizuki, Hitoshi; Izumi, Namiki; Ikeda, Fusao; Toyoda, Hidenori; Yokosuka, Osamu; Nirei, Kazushige; Genda, Takuya; Umemura, Takeji; Takehara, Tetsuo; Sakamoto, Naoya; Nishigaki, Yoichi; Nakane, Kunio; Toda, Nobuo; Ide, Tatsuya; Yanase, Mikio; Hino, Keisuke; Gao, Bing; Garrison, Kimberly L.; Dvory‐Sobol, Hadas; Ishizaki, Akinobu; Omote, Masa; Brainard, Diana; Knox, Steven; Symonds, William T.; McHutchison, John G.; Yatsuhashi, Hiroshi; Mizokami, Masashi
• Is Part Of: Journal of viral hepatitis. Volume 21:Issue 11(2014)
• Page Start: 762
• Page End: 768
• Publication Date: 2014-09-08
• Subjects: Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12312
• Languages: English
• ISSNs: 1352-0504

Abstract

<abstract abstract-type="main" id="jvh12312-abs-0001"> <title>Summary</title> <p>Genotype 2 hepatitis C virus (HCV) accounts for up to 30% of chronic HCV infections in Japan. The standard of care for patients with genotype 2 HCV – peginterferon and ribavirin for 24 weeks – is poorly tolerated, especially among older patients and those with advanced liver disease. We conducted a phase 3, open‐label study to assess the efficacy and safety of an all‐oral combination of the NS5B polymerase inhibitor sofosbuvir and ribavirin in patients with chronic genotype 2 HCV infection in Japan. We enrolled 90 treatment‐naïve and 63 previously treated patients at 20 sites in Japan. All patients received sofosbuvir 400 mg plus ribavirin (weight‐based dosing) for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after therapy (SVR12). Of the 153 patients enrolled and treated, 60% had HCV genotype 2a, 11% had cirrhosis, and 22% were over the aged 65 or older. Overall, 148 patients (97%) achieved SVR12. Of the 90 treatment‐naïve patients, 88 (98%) achieved SVR12, and of the 63 previously treated patients, 60 (95%) achieved SVR12. The rate of SVR12 was 94% in patients with cirrhosis and in those aged 65 and older. No patients discontinued study treatment due to adverse events. The most common adverse events were nasopharyngitis, anaemia and headache. Twelve weeks of sofosbuvir and ribavirin resulted in high rates of SVR12 in treatment‐naïve and previously treated patients with chronic genotype 2 HCV infection. The treatment was safe and well tolerated by patients, including the elderly and those with cirrhosis.</p> </abstract>